Foghorn Therapeutics (FHTX) Cash from Financing Activities (2019 - 2026)

Foghorn Therapeutics' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $49.8 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 35707.19% year-over-year to $49.8 million in Q1 2026; TTM through Mar 2026 was $50.7 million, a 51.48% decrease from a year earlier, with the FY2025 full-year figure at $1.0 million, down 99.03% from the prior year.
• Cash from Financing Activities rose to $49.8 million in Q1 2026 per FHTX's latest filing, from $581000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $103.2 million in Q2 2024 and bottomed at $4000.0 in Q4 2024.
• The 5-year median for Cash from Financing Activities is $333000.0 (2022), against an average of $9.4 million.
• Across the five-year window, Cash from Financing Activities sank 99.93% in 2022 and surged 100100.0% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at $16000.0 in 2022, then jumped by 1062.5% to $186000.0 in 2023, then plunged by 97.85% to $4000.0 in 2024, then soared by 14425.0% to $581000.0 in 2025, then soared by 8466.61% to $49.8 million in 2026.
• Per Business Quant, the three latest FHTX Cash from Financing Activities figures stand at $49.8 million (Q1 2026), $581000.0 (Q4 2025), and $49000.0 (Q3 2025).